Feedback / Questions
sapablursen (ONO-0530) - Ono Pharma
Sapablursen: "Met primary endpoint: Reduction in phlebotomy rate"; Polycythemia vera
(Ono Pharmaceuticals, 44th Annual J.P. Morgan Healthcare Conference)
Jan 22, 2026
P2a data
•
Hematological Malignancies • Oncology • Polycythemia Vera
https://www.ono-pharma.com/sites/default/files/44th%20Annual%20J.P.%20Morgan%20Healthcare%20Conference%20Presentation%20Material/44th_J.P.Morgan_Healthcare_conference.pdf
Jan 22, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious